Cargando…

Long-Term Effects of Angiotensin Receptor–Neprilysin Inhibitors on Myocardial Function in Chronic Heart Failure Patients with Reduced Ejection Fraction

Background. We sought to evaluate the long-term effects of angiotensin receptor blocker–neprilysin inhibitor (ARNI) therapy on reverse remodeling of the failing myocardium in HFrEF patients. Methods. We performed a prospective non-randomized longitudinal study on 228 HFrEF patients treated with ARNI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poglajen, Gregor, Anžič-Drofenik, Ajda, Zemljič, Gregor, Frljak, Sabina, Cerar, Andraž, Okrajšek, Renata, Šebeštjen, Miran, Vrtovec, Bojan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459629/ https://www.ncbi.nlm.nih.gov/pubmed/32731353 http://dx.doi.org/10.3390/diagnostics10080522

Ejemplares similares

A pilot clinical trial of cell therapy in heart failure with preserved ejection fraction
por: Vrtovec, Bojan, et al.
Publicado: (2022)

CD34(+) Cell Transplantation Improves Right Ventricular Function in Patients with Nonischemic Dilated Cardiomyopathy
por: Frljak, Sabina, et al.
Publicado: (2018)

Cell Therapy in Heart Failure with Preserved Ejection Fraction
por: Frljak, Sabina, et al.
Publicado: (2022)

Transendocardial CD34+ Cell Therapy does not Increase the Risk of Ventricular Arrhythmias in Patients with Chronic Heart Failure
por: Poglajen, Gregor, et al.
Publicado: (2019)

Favorable Response to CD34+ Cell Therapy Is Associated with a Decrease of Galectin-3 Levels in Patients with Chronic Heart Failure
por: Poglajen, Gregor, et al.
Publicado: (2019)

Transendocardial CD34(+) Cell Transplantation in Noncompaction Cardiomyopathy: First-in-Man Case Study
por: Cerar, Andraz, et al.
Publicado: (2018)

(651) Long-Term Safety and Efficacy of Mrna Sars-Cov2 Vaccination in Heart Transplant Recipients
por: Poglajen, G., et al.
Publicado: (2023)

TNF-α Predicts Endothelial Function and Number of CD34(+) Cells after Stimulation with G-CSF in Patients with Advanced Heart Failure
por: Ugovšek, Sabina, et al.
Publicado: (2022)

Outcomes of COVID-19 in Heart Transplant Recipients
por: Poglajen, G., et al.
Publicado: (2022)

Efficacy and Safety of mRNA SARS-CoV2 Vaccination in Heart Transplant Recipients
por: Poglajen, G., et al.
Publicado: (2022)

Stem Cell Therapy in Patients with Chronic Nonischemic Heart Failure
por: Poglajen, Gregor, et al.
Publicado: (2018)

Response to the letter to the editor: unravel the genetic background of noncompaction before relating it with myocardial hypoperfusion
por: Cerar, Andraz, et al.
Publicado: (2020)

Impairment of myocardial perfusion correlates with heart failure severity in patients with non‐compaction cardiomyopathy
por: Cerar, Andraz, et al.
Publicado: (2020)

Transendocardial CD34(+) Cell Therapy Improves Local Mechanical Dyssynchrony in Patients With Nonischemic Dilated Cardiomyopathy
por: Žorž, Neža, et al.
Publicado: (2022)

Effects of Transendocardial CD34(+) Cell Transplantation on Diastolic Parameters in Patients with Nonischemic Dilated Cardiomyopathy
por: Bervar, Mojca, et al.
Publicado: (2017)

Contemporary Challenges of Regenerative Therapy in Patients with Ischemic and Non-Ischemic Heart Failure
por: Banovic, Marko, et al.
Publicado: (2022)

Outcome of angiotensin receptor-neprilysin inhibitor on anxiety and depression in heart failure with reduced ejection fraction vs. heart failure with preserved ejection fraction
por: Malik, Jahanzeb, et al.
Publicado: (2021)

Clinical efficacy of angiotensin receptor-neprilysin inhibitor in de novo heart failure with reduced ejection fraction
por: Park, Su Yeong, et al.
Publicado: (2023)

Endocrine disorders after heart transplantation: national cohort study
por: Rakusa, Matej, et al.
Publicado: (2020)

Cost-Effectiveness of Earlier Transition to Angiotensin Receptor Neprilysin Inhibitor in Patients With Heart Failure and Reduced Ejection Fraction
por: Grant, Andrew D.M., et al.
Publicado: (2020)

Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40%
por: Zhao, Mingyue, et al.
Publicado: (2019)

Impact of angiotensin receptor–neprilysin inhibition on vascular function in heart failure with reduced ejection fraction: A pilot study
por: Nathaniel, Sangeetha, et al.
Publicado: (2022)

Carotid Artery Stiffness, Digital Endothelial Function, and Coronary Calcium in Patients with Essential Thrombocytosis, Free of Overt Atherosclerotic Disease
por: Vrtovec, Matjaz, et al.
Publicado: (2017)

Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40%: Retraction
Publicado: (2019)

Physician adherence and patient-reported outcomes in heart failure with reduced ejection fraction in the era of angiotensin receptor-neprilysin inhibitor therapy
por: Kim, In-Cheol, et al.
Publicado: (2022)

Comparison of Efficacy and Safety of Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis
por: Haseeb, Muhammad Talha, et al.
Publicado: (2023)

Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP‐HF
por: Chapman, Brittany, et al.
Publicado: (2022)

Long-term effects of angiotensin receptor neprilysin inhibitor therapy in heart failure patients with reduced ejection fraction: A retrospective cohort study
por: Koçak, Ajar, et al.
Publicado: (2023)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Retrospective Multi-Institutional Study
por: Hsiao, Fu-Chih, et al.
Publicado: (2022)

Efficacy and Mode of Action of Mesenchymal Stem Cells in Non-Ischemic Dilated Cardiomyopathy: A Systematic Review
por: Hoeeg, Cecilie, et al.
Publicado: (2020)

A clinical experience of Indian patients with heart failure with reduced left ventricular ejection fraction using an angiotensin receptor-neprilysin inhibitor [ARNI] on an outpatient basis
por: Jariwala, Pankaj, et al.
Publicado: (2021)

Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
por: Ryazanov, A.S., et al.
Publicado: (2023)

Lipoprotein(a)—The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation
por: Ugovšek, Sabina, et al.
Publicado: (2021)

Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall
por: Ugovšek, Sabina, et al.
Publicado: (2022)

Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure
por: Dizaye, Kawa, et al.
Publicado: (2019)

Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias
por: Sutanto, Henry, et al.
Publicado: (2021)

Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice
por: Esser, Nathalie, et al.
Publicado: (2022)

Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
por: Greenberg, Barry
Publicado: (2020)

Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?
por: Lupón, Josep, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_83kh28kido8kkdsqgb4s7a8444